Masimo Q2 Revenue Outlook Miss; Citigroup Bullish On BeiGene
- July 18th, 2023
- 335 views
Shares of Masimo Corporation (Nasdaq: MASI) experienced a significant drop of over 20% in after-hours trading following the release of preliminary revenue results that fell below expectations.
The company anticipates its consolidated revenue for the second quarter of 2023 to range from $453 million to $457 million, which is notably lower than the consensus estimate of $553.23 million.
In response to the disappointing Q2 revenues, Masimo is implementing cost-cutting measures for the second half of the year.
$MASI was trading at $110.00, down $37.16 (-25.25%) in after-hours
In other news, BeiGene, Ltd. (Nasdaq: BGNE), a leading biopharmaceutical company specializing in cancer treatment, received coverage initiation from Citigroup with a Buy rating and a price target of $275.
Based on Monday's closing price of $197.90, the indicated price target suggests a potential upside of $77.10 or approximately 38.87% for $BGNE, according to the investment firm's analysis.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025
Member Login